Current Report Filing (8-k)
31 March 2023 - 11:31PM
Edgar (US Regulatory)
0001533743
false
0001533743
2023-03-30
2023-03-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 30, 2023
Commission
file number 001-39531
PROCESSA
PHARMACEUTICALS, INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware |
|
45-1539785 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(I.R.S.
Employer
Identification Number) |
7380
Coca Cola Drive, Suite 106, Hanover, Maryland 21076 |
(Address
of Principal Executive Offices, Including Zip Code) |
(443)
776-3133 |
(Registrant’s
Telephone Number, Including Area Code) |
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common |
|
PCSA |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging
growth company ☐ |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item
2.02 Results of Operations and Financial Condition.
On
March 30, 2023, Processa Pharmaceuticals, Inc. (the “Company”) issued an earnings release announcing its financial results
for the year ended December 31, 2022. A copy of the earnings release is furnished as Exhibit 99.1 to this Current Report on Form 8-K
(this “Report”).
The
information in this Item 2.02 and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it
be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities
Act”), or the Exchange Act.
Item
7.01 Regulation FD Disclosure.
Corporate
Presentation
On
March 30, 2023, the Company posted an updated corporate presentation to its website at https://www.processapharmaceuticals.com/,
which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as
Exhibit 99.2 to this Report.
The
information in this Item 7.01 and Exhibits 99.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act
or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Exhibit
99.2 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are
based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the
limitations listed in Exhibit 99.2 and in the other reports of the Company filed with the Securities and Exchange Commission, including
that actual events or results may differ materially from those in the forward-looking statements.
Item
9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized, on March 30, 2023.
|
PROCESSA
PHARMACEUTICALS, INC. |
|
Registrant |
|
|
|
|
By: |
/s/
David Young |
|
|
David
Young |
|
|
Chief
Executive Officer |
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jul 2023 to Jul 2024